IL225689A0 - Cancer treatment/inhibition of metastasis - Google Patents

Cancer treatment/inhibition of metastasis

Info

Publication number
IL225689A0
IL225689A0 IL225689A IL22568913A IL225689A0 IL 225689 A0 IL225689 A0 IL 225689A0 IL 225689 A IL225689 A IL 225689A IL 22568913 A IL22568913 A IL 22568913A IL 225689 A0 IL225689 A0 IL 225689A0
Authority
IL
Israel
Prior art keywords
metastasis
inhibition
cancer
treatment
Prior art date
Application number
IL225689A
Other languages
English (en)
Hebrew (he)
Original Assignee
Djamgoz Mustafa Bilgin Ali
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Djamgoz Mustafa Bilgin Ali filed Critical Djamgoz Mustafa Bilgin Ali
Publication of IL225689A0 publication Critical patent/IL225689A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL225689A 2010-10-13 2013-04-10 Cancer treatment/inhibition of metastasis IL225689A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2010/001908 WO2012049440A1 (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metastasis

Publications (1)

Publication Number Publication Date
IL225689A0 true IL225689A0 (en) 2013-06-27

Family

ID=44022817

Family Applications (1)

Application Number Title Priority Date Filing Date
IL225689A IL225689A0 (en) 2010-10-13 2013-04-10 Cancer treatment/inhibition of metastasis

Country Status (13)

Country Link
US (5) US20130203764A1 (enExample)
EP (4) EP2627321A1 (enExample)
JP (1) JP2013539778A (enExample)
KR (1) KR20140032346A (enExample)
CN (2) CN103370060A (enExample)
AU (2) AU2010362412A1 (enExample)
BR (1) BR112013009086A2 (enExample)
CA (1) CA2851694C (enExample)
DK (1) DK3132791T3 (enExample)
IL (1) IL225689A0 (enExample)
RU (1) RU2013121744A (enExample)
SG (1) SG189352A1 (enExample)
WO (1) WO2012049440A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013121744A (ru) 2010-10-13 2014-11-20 Мустафа Билгин Али ДЖАМГОЗ Лечение рака/ингибирование метастазирования
WO2013123403A1 (en) * 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
WO2017091574A1 (en) * 2015-11-25 2017-06-01 Health Research, Inc. Riluzole and riluzole drug combinations for the treatment of prostate cancer
JP6465306B2 (ja) * 2016-02-04 2019-02-06 セレックス・オンコロジー・リミテッド 癌の治療/転移の阻害
IL292302B2 (en) * 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy
CN110662545A (zh) * 2017-02-10 2020-01-07 赛立斯肿瘤学创新有限公司 癌症治疗和转移抑制
US20200123544A1 (en) * 2018-10-22 2020-04-23 Celex Oncology Innovations Limited Gene therapy targeting the neonatal form of nav1.5 for treating cancer
WO2021078987A1 (en) 2019-10-24 2021-04-29 Celex Oncology Innovations Limited Combination treatments for cancer
US12624101B2 (en) 2020-01-21 2026-05-12 Celex Oncology Innovations Limited Monoclonal antibodies against neonatal Nav1.5
US20230139204A1 (en) 2020-03-09 2023-05-04 Celex Oncology Innovations Limited Measuring electric activity of cells for the evaluation of metastatic potential of cancer cells
WO2022005228A1 (ko) * 2020-07-01 2022-01-06 국립암센터 3-케토아실 coa 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2025078664A1 (en) 2023-10-12 2025-04-17 Celex Oncology Innovations Limited Treatment of metastatic or invasive brain cancer
WO2025252860A1 (en) 2024-06-04 2025-12-11 Celex Oncology Innovations Limited Ranolazine enantiomer for use in cancer treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1659136A (zh) * 2002-04-18 2005-08-24 弗吉尼亚大学专利基金会 新的钠通道阻滞剂
CA2513399A1 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US8835473B2 (en) * 2004-04-16 2014-09-16 Rutgers, The State University Of New Jersey Methods and compositions for treating cancer
US9018222B2 (en) 2006-03-27 2015-04-28 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US8394377B2 (en) * 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
US20110251144A1 (en) * 2008-09-16 2011-10-13 Massachusetts Institute Of Technology Molecular modulators of the wnt/beta-catenin pathway
RU2013121744A (ru) 2010-10-13 2014-11-20 Мустафа Билгин Али ДЖАМГОЗ Лечение рака/ингибирование метастазирования

Also Published As

Publication number Publication date
US20230202994A1 (en) 2023-06-29
AU2010362412A1 (en) 2013-05-30
US11634398B2 (en) 2023-04-25
BR112013009086A2 (pt) 2016-07-26
EP4640281A2 (en) 2025-10-29
EP3132791B1 (en) 2019-11-27
WO2012049440A1 (en) 2012-04-19
EP4640281A3 (en) 2026-01-07
AU2017202267B2 (en) 2019-01-24
US20160096812A1 (en) 2016-04-07
DK3132791T3 (da) 2020-03-09
RU2013121744A (ru) 2014-11-20
KR20140032346A (ko) 2014-03-14
CN112755029A (zh) 2021-05-07
US20130203764A1 (en) 2013-08-08
CA2851694C (en) 2019-02-26
EP3653206A1 (en) 2020-05-20
US12534444B2 (en) 2026-01-27
CA2851694A1 (en) 2012-04-19
US20200017457A1 (en) 2020-01-16
EP2627321A1 (en) 2013-08-21
EP3132791A1 (en) 2017-02-22
SG189352A1 (en) 2013-05-31
JP2013539778A (ja) 2013-10-28
US20180346431A1 (en) 2018-12-06
AU2017202267A1 (en) 2017-04-27
CN103370060A (zh) 2013-10-23

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
IL258612B (en) An anti-angiogenic drug for the treatment of ovarian cancer
IL218575A0 (en) Treatment of cancer
SG10201508495VA (en) Combination treatment of cancer
IL223189A0 (en) Methods of treatment of pancreatic cancer
IL232530A0 (en) Combined cancer treatment
ZA201304280B (en) Treatment of jak2-mediated conditions
IL238254B (en) Cancer treatment methods
EP2643001A4 (en) METHOD OF TREATING CANCER
ZA201304225B (en) Methods of treating cancer
IL228430A0 (en) Cancer treatment
IL217796A0 (en) Inhibition of tumor metastasis using bv8-or g-csf-antagonists
EP2640390A4 (en) METHODS OF TREATING CANCER
GB201012845D0 (en) Inhibition of dicer function for treatment of cancer
GB0916686D0 (en) Treatment of cancer
GB201017316D0 (en) Treatment of cancer/inhibition of metastasis
GB201113140D0 (en) Prediction and treatment of cancer
PT2560638E (pt) Método de tratamento de cancro gástrico
GB201017354D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
GB201121783D0 (en) Treatment of cancer
GB0921757D0 (en) Treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
GB201017350D0 (en) Inhibition of metastatic spread of cancer
GB201121780D0 (en) Inhibition of metastatic spread of cancer